Kommentar
In pituitary adenoma surgery, no vs. perioperative hydrocortisone was noninferior for new-onset adrenal insufficiency
Annals of Internal Medicine · 2023
DOI: 10.7326/j23-0013 ↗Kurz gefasst
Kommentar in der Zeitschrift Annals of Internal Medicine, 2023. Verfasst von Gunjan Y Gandhi. Beteiligte Einrichtung: University of Florida, Jacksonville, Florida, USA (G.Y.G.). Hauptthemen laut MEDLINE: Adenoma, Adrenal Insufficiency, Pituitary Neoplasms.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
AdenomaAdrenal InsufficiencyPituitary NeoplasmsHumansGlucocorticoidsHydrocortisoneHypothalamo-Hypophyseal SystemRandomized Controlled Trials as Topic
Substanzen
GlucocorticoidsHydrocortisone
Autor:innen und Institutionen
- University of Florida, Jacksonville, Florida, USA (G.Y.G.).
Zitieren
APA
Gandhi, G. Y. (2023). In pituitary adenoma surgery, no vs. perioperative hydrocortisone was noninferior for new-onset adrenal insufficiency. Annals of Internal Medicine. https://doi.org/10.7326/j23-0013
Vancouver
Gandhi GY. In pituitary adenoma surgery, no vs. perioperative hydrocortisone was noninferior for new-onset adrenal insufficiency. Annals of Internal Medicine. 2023. doi:10.7326/j23-0013
BibTeX
@article{Gandhi2023,
author = {Gandhi, Gunjan Y},
title = {In pituitary adenoma surgery, no vs. perioperative hydrocortisone was noninferior for new-onset adrenal insufficiency},
journal = {Annals of Internal Medicine},
year = {2023},
doi = {10.7326/j23-0013}
}
EUVIMED